|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Rheumatoid Arthritis - DMARDs Gain Ground as Biologics Competition Intensifies
Datamonitor, July 2004, Pages: 192
The treatment of RA has changed significantly as treatment shifts towards early, aggressive management of the disease.
Although guidelines support early use of DMARDs, concomitant use of other drugs, such as NSAIDs, continues at significant levels.
The convenience of Humira is challenging Enbrel and Remicade, and Medicare reform in the US promises to alter radically the dynamics of this sector.
Scope of Report:
Assessment of epidemiological trends and patient potential
Analysis of RA treatment algorithms globally and by country, based on extensive primary research with 180 physicians
Country treatment trees showing treatment practices in the seven major markets
Transcripts of interviews with key RA opinion leaders in the US, UK, and mainland Europe
Report Highlights:
The addition of a prescription drug benefit to Medicare will have significant effects on the RA market and treatment practices, in particular in the biologics sector. The advantage over its rivals of Remicade as an infusion product reimbursed under Medicare is set to narrow, transforming the dynamics of the biologic DMARDs sector.
Celltech and CAT have had licenses for RA products disputed or terminated, with serious consequences for licensors and licensees. Big pharma’s need to boost pipelines through licensing makes it important that companies refrain from alienating biotechs, to avoid jeopardizing opportunities to conclude much needed licensing deals with future partners.
65 and overs account for 53% of US RA patients. 70% of 65-74s voted in the US election of 2000, to just 44% of 25-34s. The demographics of population and disease favor RA as a disease where advocacy groups should possess a powerful voice, but polarization of political issues makes it hard for RA groups to leverage their advantages in lobbying.
Reasons to Purchase:
Explore changing RA treatment patterns across the seven major markets to understand differences in prescribing patterns
Understand why Medicare reform and changes in reimbursement status are a key issue in the US RA market
In a sector heavily dependent on licensing deals, appreciate why big pharma needs to worry about alienating potential partners
Customers who bought this item also bought
Treatment Algorithms: Rheumatoid Arthritis 2nd Edition - Dmards Move to Front of Pack
Stakeholder Insight: Rheumatoid Arthritis - Biologics Battle Up the Treatment Algorithm
Stakeholder Insight: Inflammatory Bowel Disease - Debate over early aggressive treatment continues
Commercial and Pipeline Perspectives: Rheumatoid Arthritis - Novel Biologics Drive Innovation in the Global RA Market
Stakeholder Opinions: Systemic Lupus Erythematosus - Market Set to Enter Era of Biologic Therapies
Autoimmune Treatment (2009 - 2014)
Osteoarthritis and Rheumatoid Arthritis: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Product Performance and Closing the Need Gap
Stakeholder Insight: Parkinsons Disease - Evidence of neuroprotection essential to progress treatment dynamics
Disease Modification in Rheumatoid Arthritis - The Biologics Boom
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Physician Perception of Biologics in Autoimmune Disease - Targeted Detailing is the Key to Success
|
|
|
|
